Stop Drug Shortages, Start Domestic Supply Chains
2020
Phlow Aims to Revamp Drug Supply Chain
How Phlow is revamping the way medicines are made and distributed.
The US Wants to Use Covid-19 to Insource Drug Manufacturing
Phlow’s mission to reliably supply affordable, high-quality, essential medicines through U.S.-based advanced manufacturing processes.
Phlow Receives Inno on Fire Award in Crisis Innovators Category
Phlow honored with “Inno on Fire” Award for its impact on U.S.-based pharmaceutical manufacturing of essential medicines.
Trump Takes a First Step Toward Returning Medical Supply Chains to the U.S.
White House officials called the multi-million dollar contract with Virginia-based Phlow Corp. a potential landmark in returning pharmaceutical manufacture from overseas.
Phlow CEO Dr. Eric Edwards on Federal Contract to Make Covid-19 Drugs
Dr. Eric Edwards, CEO of Phlow Corp., joins “Squawk Alley” to discuss manufacturing essential medicines in the U.S.
Richmond Startup Awarded $354 Million Federal Contract to Make Ingredients for Covid-19 Drugs
A new Richmond-based pharmaceutical manufacturing company has received a $354 million federal contract to help build a strategic, national reserve of essential medications and to make active ingredients for more than a dozen medicines used to treat patients with COVID-19.
Phlow Awarded Contract for Coronavirus Drug Development in US
Phlow CEO Eric Edwards discusses manufacturing coronavirus treatments and other critical drugs in shortage in partnership with the U.S. government.
New Pharma Company Lands $354 Million Government Contract to Produce Coronavirus Drugs in the U.S.
Move Strengthens America’s Supply Chain and Supports COVID-19 Response.
New Pharma Company Lands $354 Million Government Contract to Produce Coronavirus Drugs in the U.S.
The U.S. government signed a $354 million four-year contract with new pharmaceutical company Phlow Corp. to increase American production of medications that may help treat Covid-19 in a bid to avoid potential supply chain shortages, with the potential to extend the contract to $812 million for the next ten years.